Profiel
Dr. Martin D.
Meglasson is Chief Scientific Officer & Vice President at Bellerophon Therapeutics, Inc.
Dr. Meglasson was previously employed as Chief Scientific Officer by Ikaria, Inc., Vice President-Discovery Research by Ligand Pharmaceuticals, Inc., a Director-Preclinical Pharmacology by Pharmacia, Inc., and a Director-Endocrine & Metabolic Research by Pharmacia & Upjohn, Inc.
He received his doctorate degree from the University of Houston.
Eerdere bekende functies van Martin D. Meglasson
| Bedrijven | Functie | Einde |
|---|---|---|
| IKARIA, INC. | Hoofd Techniek/Wetenschap/O&O | 01-01-2014 |
| LIGAND PHARMACEUTICALS INCORPORATED | Corporate Officer/Principal | 23-07-2010 |
| Pharmacia, Inc. | Hoofd Techniek/Wetenschap/O&O | 01-01-2003 |
| Pharmacia & Upjohn, Inc. | Corporate Officer/Principal | 01-01-1998 |
| BELLEROPHON THERAPEUTICS, INC. | Hoofd Techniek/Wetenschap/O&O | - |
Opleiding van Martin D. Meglasson
| University of Houston | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 2 |
|---|---|
| LIGAND PHARMACEUTICALS INCORPORATED | Health Technology |
| BELLEROPHON THERAPEUTICS, INC. | Health Technology |
| Bedrijven in privébezit | 3 |
|---|---|
| Pharmacia & Upjohn, Inc. | Health Technology |
| Pharmacia, Inc. | |
Ikaria, Inc.
 Ikaria, Inc. BiotechnologyHealth Technology Ikaria, Inc. operates as a biotherapeutics company focused on developing and commercializing innovative therapeutics and interventions designed to meet the medical needs of critically ill patients. It offers INOMAX for inhalation, which is used to treat newborns suffering from hypoxic respiratory failure, and is making a major impact on the critical care environment. The company was founded on August 18, 2006 and is headquartered in Clinton, NJ. | Health Technology |
